|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
USRE38008E1
(en)
|
1986-10-09 |
2003-02-25 |
Neorx Corporation |
Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5191066A
(en)
|
1990-12-07 |
1993-03-02 |
Abbott Laboratories |
Site-specific conjugation of immunoglobulins and detectable labels
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
CA2116774C
(en)
|
1991-09-19 |
2003-11-11 |
Paul J. Carter |
Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
|
|
US6146850A
(en)
|
1991-11-04 |
2000-11-14 |
Xoma Corporation |
Proteins encoding gelonin sequences
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5981194A
(en)
|
1992-07-10 |
1999-11-09 |
University Of British Columbia |
Use of p97 and iron binding proteins as diagnostic and therapeutic agents
|
|
CA2140280A1
(en)
|
1992-08-17 |
1994-03-03 |
Avi J. Ashkenazi |
Bispecific immunoadhesins
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
WO1997034631A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
WO1997035589A1
(en)
|
1996-03-26 |
1997-10-02 |
Kopreski Michael S |
Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
|
|
US6753165B1
(en)
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
EP1034298B1
(en)
|
1997-12-05 |
2011-11-02 |
The Scripps Research Institute |
Humanization of murine antibody
|
|
WO1999037779A1
(en)
|
1998-01-22 |
1999-07-29 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
|
|
WO2000012508A2
(en)
|
1998-08-27 |
2000-03-09 |
Spirogen Limited |
Pyrrolbenzodiazepines
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
|
JP4414023B2
(ja)
*
|
1999-08-05 |
2010-02-10 |
オリエンタル酵母工業株式会社 |
関節炎関連メラノトランスフェリンの測定方法および試薬
|
|
WO2001059459A2
(en)
|
2000-02-08 |
2001-08-16 |
University Of British Columbia |
Compositions and methods for screening therapeutic agents
|
|
KR20020007432A
(ko)
|
2000-07-13 |
2002-01-29 |
박현석 |
멜라노트랜스페린에 대한 단클론 항체를 유효성분으로포함하는 알츠하이머병의 진단시약
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
US6362331B1
(en)
|
2001-03-30 |
2002-03-26 |
Council Of Scientific And Industrial Research |
Process for the preparation of antitumor agents
|
|
EP1256354A1
(en)
|
2001-05-11 |
2002-11-13 |
Schering Corporation |
Methods for treating cancer
|
|
TW200303759A
(en)
|
2001-11-27 |
2003-09-16 |
Schering Corp |
Methods for treating cancer
|
|
EP1553975B8
(en)
|
2002-09-27 |
2023-04-12 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
US7608429B2
(en)
|
2002-10-31 |
2009-10-27 |
Genentech, Inc. |
Methods and compositions for increasing antibody production
|
|
EP1419786A1
(en)
|
2002-11-13 |
2004-05-19 |
Bracco Imaging S.p.A. |
Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof
|
|
GB0226593D0
(en)
|
2002-11-14 |
2002-12-24 |
Consultants Ltd |
Compounds
|
|
ES2897506T3
(es)
|
2003-01-09 |
2022-03-01 |
Macrogenics Inc |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
|
|
US7619068B2
(en)
|
2003-05-09 |
2009-11-17 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
|
EP1626735B1
(en)
*
|
2003-05-09 |
2014-11-19 |
Transfert Plus |
Compound for treating cancer caused by cells expressing melanotransferrin at their surface
|
|
GB0315457D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
AU2004273791A1
(en)
|
2003-09-05 |
2005-03-31 |
Genentech, Inc. |
Antibodies with altered effector functions
|
|
GB0321295D0
(en)
|
2003-09-11 |
2003-10-15 |
Spirogen Ltd |
Synthesis of protected pyrrolobenzodiazepines
|
|
US7807392B1
(en)
|
2003-09-15 |
2010-10-05 |
Celera Corporation |
Lung disease targets and uses thereof
|
|
PT1720881E
(pt)
|
2004-03-01 |
2013-02-04 |
Spirogen Sarl |
Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2
|
|
GB0404577D0
(en)
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
|
EP1725586B1
(en)
|
2004-03-02 |
2015-01-14 |
Seattle Genetics, Inc. |
Partially loaded antibodies and methods of their conjugation
|
|
US7189710B2
(en)
|
2004-03-30 |
2007-03-13 |
Council Of Scientific And Industrial Research |
C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
|
|
FR2869231B1
(fr)
|
2004-04-27 |
2008-03-14 |
Sod Conseils Rech Applic |
Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
|
|
CN101065151B
(zh)
|
2004-09-23 |
2014-12-10 |
健泰科生物技术公司 |
半胱氨酸改造的抗体和偶联物
|
|
EP1817341A2
(en)
|
2004-11-29 |
2007-08-15 |
Seattle Genetics, Inc. |
Engineered antibodies and immunoconjugates
|
|
DK1874821T3
(da)
|
2005-04-26 |
2013-07-08 |
Trion Pharma Gmbh |
Kombination af antistoffer med glykokortikoider til behandling af kræft
|
|
WO2006116260A2
(en)
|
2005-04-26 |
2006-11-02 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
|
GB0514779D0
(en)
|
2005-07-19 |
2005-08-24 |
Celltech R&D Ltd |
Biological products
|
|
US7521195B1
(en)
|
2005-07-21 |
2009-04-21 |
Celera Corporation |
Lung disease targets and uses thereof
|
|
US20070123448A1
(en)
|
2005-11-23 |
2007-05-31 |
The Hospital For Sick Children |
Novel chemical entities affecting neuroblastoma tumor-initiating cells
|
|
ATE527262T1
(de)
|
2006-01-25 |
2011-10-15 |
Sanofi Sa |
Neue tomaymycin derivate enhaltende zytotoxische mittel
|
|
NZ597251A
(en)
|
2006-05-30 |
2013-08-30 |
Genentech Inc |
Antibodies and immunoconjugates and uses therefor
|
|
CN101501187A
(zh)
|
2006-06-06 |
2009-08-05 |
田纳西大学研究基金会 |
富含赘生干细胞的组合物及包含其的方法
|
|
US20080220448A1
(en)
|
2006-09-01 |
2008-09-11 |
Blincko Stuart J |
Antigenic protein conjugates and process for preparing same
|
|
CA3153438C
(en)
|
2006-09-07 |
2024-03-12 |
Scott & White Memorial Hospital |
Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
|
|
GB0619291D0
(en)
|
2006-09-29 |
2006-11-08 |
Ucb Sa |
Altered antibodies
|
|
US8309354B2
(en)
|
2007-01-22 |
2012-11-13 |
Macrogenics West, Inc. |
Human cancer stem cells
|
|
CL2008001334A1
(es)
|
2007-05-08 |
2008-09-22 |
Genentech Inc |
Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
|
|
EP2022848A1
(en)
|
2007-08-10 |
2009-02-11 |
Hubrecht Institut |
A method for identifying, expanding, and removing adult stem cells and cancer stem cells
|
|
US8865875B2
(en)
|
2007-08-22 |
2014-10-21 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
|
|
KR20100052545A
(ko)
|
2007-08-28 |
2010-05-19 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Igf―1r의 다중 에피토프에 결합하는 조성물
|
|
EP4512422A3
(en)
|
2007-09-14 |
2025-05-21 |
Amgen Inc. |
Homogenous antibody populations
|
|
US20090155255A1
(en)
|
2007-09-27 |
2009-06-18 |
Biogen Idec Ma Inc. |
Cd23 binding molecules and methods of use thereof
|
|
CN102083460A
(zh)
|
2008-01-18 |
2011-06-01 |
米迪缪尼有限公司 |
用于位点特异性偶联的半胱氨酸工程化抗体
|
|
WO2010037134A2
(en)
|
2008-09-29 |
2010-04-01 |
Stemlifeline, Inc. |
Multi-stage stem cell carcinogenesis
|
|
US20120071634A1
(en)
|
2009-03-19 |
2012-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody Constant Region Variant
|
|
US20110020221A1
(en)
|
2009-04-09 |
2011-01-27 |
The Johns Hopkins University |
Cancer stem cell expression patterns and compounds to target cancer stem cells
|
|
KR101776976B1
(ko)
|
2010-02-21 |
2017-09-08 |
바이엘 헬스케어 엘엘씨 |
생체분자의 활성화 및 접합 방법
|
|
US10435458B2
(en)
|
2010-03-04 |
2019-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variants with reduced Fcgammar binding
|
|
EP2558475A1
(en)
|
2010-04-15 |
2013-02-20 |
Spirogen Sàrl |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
|
CN103068405A
(zh)
*
|
2010-04-15 |
2013-04-24 |
西雅图基因公司 |
靶向吡咯并苯并二氮杂卓结合物
|
|
GB201006340D0
(en)
|
2010-04-15 |
2010-06-02 |
Spirogen Ltd |
Synthesis method and intermediates
|
|
RS52983B
(sr)
|
2010-04-15 |
2014-02-28 |
Spirogen Sárl |
Pirolobenzodiazepini i njihovi konjugati
|
|
CN119552249A
(zh)
|
2010-06-08 |
2025-03-04 |
基因泰克公司 |
半胱氨酸改造的抗体和偶联物
|
|
US20130061340A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc. |
Identification and Enrichment of Cell Subpopulations
|
|
US9778264B2
(en)
|
2010-09-03 |
2017-10-03 |
Abbvie Stemcentrx Llc |
Identification and enrichment of cell subpopulations
|
|
WO2013119964A2
(en)
|
2012-02-08 |
2013-08-15 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
|
AU2011295722B2
(en)
|
2010-09-03 |
2016-04-21 |
Abbvie Stemcentrx Llc |
Identification and enrichment of cell subpopulations
|
|
US20130061342A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc. |
Identification and Enrichment of Cell Subpopulations
|
|
EP3444267B1
(en)
|
2010-09-17 |
2020-09-09 |
National Institute of Advanced Industrial Science and Technology |
Lung cancer differential marker
|
|
JP6014596B2
(ja)
|
2010-11-09 |
2016-10-25 |
メディミューン,エルエルシー |
均一コンジュゲーションのための抗体足場
|
|
WO2012078761A2
(en)
|
2010-12-09 |
2012-06-14 |
Bayer Healthcare Llc |
Dimeric molecular complexes with free cysteine residues and conjugates thereof
|
|
RS56793B1
(sr)
|
2011-03-02 |
2018-04-30 |
Roche Glycart Ag |
Cea antitela
|
|
BR112014002219A2
(pt)
*
|
2011-07-05 |
2018-08-07 |
Bioasis Technologies Inc |
conjugados anticorpo p97 e métodos de sua utilização
|
|
ES2654111T3
(es)
|
2011-08-05 |
2018-02-12 |
Bioasis Technologies Inc. |
Fragmentos p97 con actividad de transferencia
|
|
JP2014530825A
(ja)
|
2011-10-19 |
2014-11-20 |
セラテクノロジーズ・インコーポレーテッド |
メラノトランスフェリン由来のペプチド化合物及びその使用
|
|
KR20110136776A
(ko)
*
|
2011-12-12 |
2011-12-21 |
경북대학교 산학협력단 |
당뇨병성 신증 진단용 바이오마커 및 이의 동정방법
|
|
ES2816078T3
(es)
|
2011-12-20 |
2021-03-31 |
Medimmune Llc |
Polipéptidos modificados para armazones de anticuerpo biespecífico
|
|
CA3111357A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
SG10201801444WA
(en)
*
|
2012-02-24 |
2018-04-27 |
Abbvie Stemcentrx Llc |
Anti sez6 antibodies and methods of use
|
|
BR112014022228A2
(pt)
|
2012-03-08 |
2017-07-11 |
Halozyme Inc |
anticorpos anti-epidérmicos de receptor de fator de crescimento condicionalmente ativo e métodos de uso dos mesmos
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
WO2013177481A1
(en)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazepines and conjugates thereof
|
|
JP6109937B2
(ja)
*
|
2012-07-20 |
2017-04-05 |
クリーブ バイオサイエンシズ インコーポレイテッド |
p97複合体の阻害剤としての融合ピリミジン
|
|
JP6273205B2
(ja)
|
2012-10-05 |
2018-01-31 |
協和発酵キリン株式会社 |
ヘテロダイマータンパク質組成物
|
|
EP2839860B1
(en)
|
2012-10-12 |
2019-05-01 |
MedImmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
PT3470086T
(pt)
|
2012-10-12 |
2021-02-01 |
Medimmune Ltd |
Pirrolobenzodiazepinas e conjugados das mesmas
|
|
AU2014214751B2
(en)
|
2013-02-08 |
2017-06-01 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
|
US9968687B2
(en)
|
2013-02-22 |
2018-05-15 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibody drug conjugates
|
|
ES2774549T3
(es)
|
2013-03-13 |
2020-07-21 |
Bioasis Technologies Inc |
Fragmentos de P97 y usos de los mismos
|
|
KR20160018579A
(ko)
|
2013-06-04 |
2016-02-17 |
싸이톰스 테라퓨틱스, 인크. |
활성화가능 항체를 접합하기 위한 조성물 및 방법
|
|
KR20210115051A
(ko)
|
2013-06-10 |
2021-09-24 |
다나-파버 캔서 인스티튜트 인크. |
종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
|
|
EP3024456A4
(en)
|
2013-07-26 |
2017-04-12 |
Update Pharma Inc. |
Combinatorial methods to improve the therapeutic benefit of bisantrene
|
|
BR112016004242A8
(pt)
|
2013-08-28 |
2018-06-12 |
Stemcentrx Inc |
Métodos para conjugação sítio-específica de anticorpos e composições
|
|
US20150093399A1
(en)
|
2013-08-28 |
2015-04-02 |
Bioasis Technologies, Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
WO2015123265A1
(en)
|
2014-02-11 |
2015-08-20 |
Seattle Genetics, Inc. |
Selective reduction of proteins
|
|
AU2015218633A1
(en)
|
2014-02-21 |
2016-09-01 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibodies and drug conjugates for use in melanoma
|
|
WO2016064749A2
(en)
|
2014-10-20 |
2016-04-28 |
Igenica Biotherapeutics, Inc. |
Novel antibody-drug conjugates and related compounds, compositions, and methods of use
|